Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; silicon dioxide; disodium edetate; sodium benzoate; xanthan gum; saccharin sodium; sorbitol; flavour - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 25 mg/ml - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; silicon dioxide; disodium edetate; sodium benzoate; xanthan gum; saccharin sodium; sorbitol; flavour - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 287 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; mannitol; water for injections; nitrogen - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; nitrogen; mannitol; water for injections - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; mannitol; water for injections; nitrogen - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; nitrogen; mannitol; water for injections - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

United States - English - NLM (National Library of Medicine)

cumberland pharmaceuticals inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 20 mg - omeclamox-pak (omeprazole delayed-release capsules, clarithromycin tablets, and amoxicillin capsules taken together) are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or one-year history) to eradicate h. pylori in adults. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.1) ]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of omeclamox-pak and other antibacterial drugs omeclamox-pak should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. omeclamox-pak is contraindicated in the following patients: - known history of h

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amoxicillin trihydrate -